References
- Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471–476.
- O’Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiogenesis receptor is located on chromosome 11. Gene. 1993;136:355–360.
- Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypertensive action. Endocrinology. 2005;146:231–236.
- Kagiyama S, Fukuhara M, Matsumura K, et al. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept. 2005;125:55–59.
- Japp AG, Cruden NL, Amer DA, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52:908–913.
- Siddiquee K, Hampton J, McAnally D, et al. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol. 2013;168:1104–1117.
- Wu H, Cheng XW, Hao C, et al. Regulation of apelin and its receptor expression in adipose tissues of obesity rats with hypertension and cultured 3T3-L1 adipocytes. Exp Anim. 2014;63:257–267.
- Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013;216:17–36.
- Japp AG, Cruden NL, Barnes G, et al. Acute cardiovascular effects of Apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121:1818–1827.
- Zhu P, Huang F, Lin F, et al. Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population. Ann Med. 2013;45:494–498.
- Fava C, Sjogren M, Montagnana M, et al. Prediction of blood pressure changes over time and incidence of hypertension by a genetic risk score in Swedes. Hypertension. 2013;61:319–326.
- Cowley AW. The genetic dissection of essential hypertension. Nat Rev Genet. 2006;7:829–840.
- Li WW, Niu WQ, Zhang Y, et al. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens. 2009;27:1194–1201.
- Liao YC, Chou WW, Li YN, et al. Apelin gene polymorphism influences apelin expression and obesity phenotypes in Chinese women. Am J Clin Nutr. 2011;94:921–928.
- Zhao Q, Hixson JE, Rao DC, et al. Genetic variants in the apelin system and blood pressure responses to dietary sodium interventions: a family-based association study. J Hypertens. 2010;28:756–763.
- Zhao Q, Gu D, Kelly TN, et al. Association of genetic variants in the apelin–APJ system and ACE2 with blood pressure responses to potassium supplementation: the GenSalt study. Am J Hypertens. 2010;23:606–613.
- Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572.
- American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care. 2011;34(Suppl 1):S11–S61.
- Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34–41.
- Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene–gene and gene environment interactions. Bioinformatics. 2003;19:376–382.
- Moore J. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered. 2003;56:73–82.
- Phillips PC. Epistasis. The essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet. 2008;9:855–867.
- Ritchie M, Hahn L, Roodi N. Multifactor-dimensionality reduction reveals high-order interactions among estro-metabolism genes in sporadic breast cancer. Am J Hum Genet. 2001;69:138–147.